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sifteen years ago in this Journal, Brugada and Brugada (1)
eported a new syndrome with ST-segment elevation in
CG leads V1 to V3, right bundle branch appearance during
inus rhythm, and a high incidence of ventricular fibrillation
VF) and sudden cardiac death. There were 8 patients (6
ales and 2 females) in that original report. Patient #7, an
-year-old girl, was the only 1 with a history of paroxysmal
trial fibrillation (AF). The paroxysmal AF occurred soon
fter birth, and the first episode of syncope occurred at the
ge of 8 years. She was a subject in another case report 12
ears later because of multiple documented episodes of VFs
nduced by short-coupled premature ventricular contrac-
ions (2). Programmed stimulation induced nonsustained
olymorphic ventricular tachycardia in 3 patients at baseline
nd during isoproterenol infusion. In 4 patients, including
atient #7, the same programmed stimulation induced VF.
See pages 1154, 1162, and 1169
n this issue of the Journal, 3 articles (3–5) provided new
nsights into the characteristic T-wave changes in Brugada
yndrome, the prevalence of AF, and the mechanisms that
etermine the inducibility of VF during electrophysiological
tudies. These studies have significantly advanced the un-
erstanding of Brugada syndrome.
revalence of Brugada syndrome. Though uncommon in
he rest of the world, sudden unexpected death syndrome
SUDS) in East Asia and Southeast Asia is a major cause of
eath in young men without known underlying cardiac
iseases (6). Similar clinical manifestations were also found
n the U.S. among immigrants from Southeast Asia (7),
uggesting a genetic basis of this disease. Roughly 80% of
he clinically affected patients are male, and the sudden
eath typically occurs at night. Epidemiological studies in
apan showed the prevalence of Brugada syndrome to be
rom 0.12% to 0.14% in the general population (8,9).
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From †Krannert Institute of Cardiology, Division of Cardiology Department of
edicine, Indiana University School of Medicine, Indianapolis, Indiana; and ‡Uni-
ersity of Pavia and the Molecular Cardiology and Electrophysiology Laboratories,
RCCS Fondazione Salvatore Maugeri, Pavia, Italy. Supported by the Nationalm
nstitutes of Health grants P01 HL78931, R01 HL78932, 71140, and Medtronic-
ipes Endowments.enetic basis of Brugada syndrome. Roughly 15% to 20%
f the patients with Brugada syndrome had mutations at the
lpha subunit of the sodium channel gene (SCN5A) (10,11).
ince the first report by Chen et al. (12), over 100 different
utations of SCN5A have been identified and more mu-
ations are being added to the list on a regular basis (13). In
ddition to the mutations of the sodium channel itself,
utations of genes that modulate sodium channel function
re also associated with Brugada syndrome. For example,
utation of the ankyrin-binding motif of Nav1.5 results in
loss of binding of Nav1.5 with its intracellular target chaperon
nkyrin G, leading to Brugada syndrome (14). Mutation of
lycerol-3-phosphate dehydrogenase 1-like (GPD1-L) gene
ay affect trafficking of the sodium channel to the cell surface,
hich in turn reduces sodium current and causes Brugada
yndrome (15). Abnormalities of the sodium current are not
he only genetic defects identified in Brugada syndrome.
ntzelevitch et al. (16) screened 82 consecutive probands of
rugada syndrome patients for ion channel mutations. In 7 of
he 82 (8.5%) patients, there were mutations in genes encoding
he cardiac L-type calcium channel. Among them, 3 exhibited
new clinical entity of short QT interval, sudden death, and
ype-1 Brugada ECGs. These findings indicate that, in addi-
ion to abnormalities of sodium currents, the reduced calcium
urrent can also contribute to the development of Brugada
yndrome. However, the genetic basis of the majority of the
atients remains unclear. Because different genetic defects
ay result in different phenotypes, large gaps of knowledge
xist in the understanding of not only the genetic basis, but
lso the clinical manifestations of the diseases.
he Brugada ECG: abnormalities of ST-T waves. The
CG patterns associated with typical Brugada syndrome
ere first reported by Martini et al. (17). Subsequent studies
howed 3 different types of ECG changes to be associated
ith Brugada syndrome based on the morphology in V1 and
2 (18). Type-1 ECG is characterized by a 2-mm J-point
levation, coved type ST-T segment elevation, and inverted
-wave in leads V1 and V2 (Fig. 1A). Type-2 ECG is
haracterized by a 2-mm J-point elevation, 1-mm ST-
egment elevation, saddleback ST-T segment, and a positive or
iphasic T-wave. Type-3 ECG is the same as type 2, except
hat the ST-segment elevation is 1 mm. Among these 3
ypes of ECGs, only the type 1 is diagnostic of Brugada
yndrome. A simple method to document type-1 ECG is to
ove the V1 lead from the third intercostal’s space to the
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March 25, 2008:1176–80 Editorial Commentecond intercostal’s space. However, the sensitivity and
pecificity of the diagnosis established with upward dis-
lacement of leads are unknown. Another method is to take
n ECG after a large meal (19), which is positive in
pproximately one-half of the patients. If these simple
aneuvers do not work, infusion of sodium channel block-
rs might prove effective (20). The commonly used drugs for
his test include intravenous flecainide, ajmaline, pilsicain-
de, and procainamide. The latter is the favorite in the U.S.,
s the other 3 are not readily available. However, it is
mportant to note that the previous, large studies of Brugada
yndrome (21,22) have used either flecainide or ajmaline. The
iagnostic accuracy of the procainamide test remains unknown.
he ability of the sodium channel blockade to induce type-1
CG patterns of Brugada syndrome supports a causal
elationship between the reduced sodium current and the
eneration of the type-1 ECG. The putative mechanism
23) is that after the sodium channel blockade, the transient
utward current (Ito) was unopposed, resulting in abbrevi-
ted action potential in some cells (epicardium 1 in Fig. 1B).
ther cells have delayed onset of phase 2 due to the strong,
nopposed Ito that prolonged phase 1 of the action potential
epicardium 2 in Fig. 1B). The weaker Ito in the endocar-
ium allows its action potential to maintain the usual
orphology. The vector between endocardium and epicar-
Figure 1 Type-1 ECG From Patient #7
of the Original Brugada Report
This ECG (2) was taken 10 years after that original report (1). Panel A shows
ECG of V1 with a J-point elevation (a), coved-type ST-T segment elevation (b),
and inverted T- wave (c). The T-wave morphology is not constant, and the
inverted T-wave was not seen in the next beat (d). There is a biphasic P-wave
with prolonged P-wave duration (e). Panel B shows action potential recorded
from experimental models of Brugada syndrome (23). Panel C shows 3 layers
of action potentials superimposed, with a first arrow pointing to the timing of
ST-segment elevation (point a of panel A) and a second arrow pointing to
T-wave inversion (point c of panel A). This figure was adapted with permission
from Gang et al. (2) and Fish and Antzelevitch (23).ium during phase 1 accounts for the ST-segment elevation spoint a in Fig. 1A). The prolonged action potential of
picardium 2 accounts for the vector that created the
egative terminal T-wave (point c in Fig. 1A). Because Ito
s stronger in male patients than in female patients, and in
he right ventricle than in the left ventricle, this hypothesis
icely matches the clinical manifestation of Brugada syn-
rome (18). To test whether or not this hypothesis applies
o human patients, Nagase et al. (5) inserted a catheter in
he conus branch of the right coronary artery to measure the
lectrograms from the right ventricular outflow tract. They
lso placed an endocardial catheter in the right ventricular
ndocardium to measure endocardial electrograms. Using
he activation-recovery interval (ARI) to estimate the action
otential duration (APD), the investigators were able to
etermine the differences of APD between the epicardium and
he endocardium both at baseline and after the infusion
f pilsicainide, a commonly used sodium channel blocker
n Japan. The primary finding was that the ARI at the
picardium was longer than the endocardium when the
ype-1 ECG pattern was recorded, which is consistent with
he experimental data shown in Figure 1B. In contrast,
one of the normal control patients had type-1 ECGs
nduced by pilsicainide infusion. They propose that these
ndings are consistent with the hypothesis that both
odium current and Ito played important roles in the
eneration of the type-1 ECG.
The investigators ought to be congratulated for their
bility to record ARI simultaneously from the epicardium
nd endocardium. This new approach provided important
upport for the Antzelevitch et al. (1) hypothesis of ST-T
ave changes in Brugada syndrome. However, there are also
couple of very interesting additional findings in the study.
irst, if the reduced sodium current is the only mechanism
or the ECG patterns of Brugada syndrome, then pilsicain-
de, which blocks sodium current, should induce Brugada-
ype ECGs in all patients. However, the investigators
eported that the ARI at both epicardial and endocardial
ites of normal control patients decreased after pilsicainide
dministration. Second, the investigators found that the
CN5A mutation was found in only 4 of the 19 patients
ith Brugada syndrome, but pilsicainide-induced type-1
CGs and epicardial ARI prolongation were found in all
rugada syndrome patients. These findings suggest that the
rugada-type ECG cannot be explained solely by a reduc-
ion of sodium current. A possible additional factor is a
utation involving other ionic currents, such as the calcium
urrent (16). Alternatively, it could also be related to structural
bnormalities that can affect the activation and repolarization
haracteristics of the hearts. In fact, endomyocardial biopsy of
atients with Brugada syndrome has a high yield for
etecting hidden histological abnormalities that could con-
ribute to the clinical phenotypes of Brugada syndrome (24).
he Brugada ECG: abnormalities of P waves. In addition
o the abnormalities of the ST-T segments, the Brugada ECG
s also characterized by abnormalities of the P waves. Figure 1A
hows an example of abnormally prolonged and biphasic P
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Editorial Comment March 25, 2008:1176–80aves in a patient with both paroxysmal AF and VF. Yamada
t al. (25) found that filtered P-wave duration was significantly
ncreased in patients with Brugada syndrome and Brugada-
ype ECGs in comparison with control subjects. Electrophys-
ological studies showed induction of both AF and VF in these
atients. Yokokawa et al. (26) found that P-wave duration in
atients with the SCN5A mutation is 155  19 ms, much
onger than the P wave in patients without SCN5A mutation
119  16 ms). These findings suggest that the reduced
odium current and the intra-atrial conduction velocity under-
ie the mechanisms of increased P-wave duration in patients
ith Brugada syndrome.
F in Brugada syndrome. In this issue of the Journal,
usano et al. (4) provided new insights into the mechanisms
f AF in Brugada syndrome. The investigators studied 73
atients and found spontaneous AF in 10 of them. Among
atients with documented VF, there is a higher incidence of
pontaneous AF, the inducibility of AF by extrastimuli and
rolonged interatrial conduction time. This study is an
xtension of a similar study reported in 2002, in this Journal,
n which the same group of investigators (11) reported a
igh incidence of AF (7 of 18) in patients with Brugada
yndrome. With the increased number of patients, the
ncidence of AF dropped to 10 of 73, which is similar to that
riginally reported by Brugada and Brugada (1). In addition,
n association between AF and VF was documented in the
resent study. This latter finding is consistent with a report
y Bigi et al. (27), who showed that the most important
redictor of AF in Brugada syndrome is the occurrence of
revious life-threatening cardiac events.
Kusano et al. (4) reported that just like VF, the AF in
atients with Brugada syndrome occurs mostly (70%) at
ight. It is generally assumed that the vagal tone is higher at
ight than during the day. However, Ogawa et al. (28)
ecently reported, in this Journal, the results of simultaneous
ympathetic and vagal nerve recordings in ambulatory dogs
4 h a day, 7 days a week. They found a clear circadian
ariation of sympathetic nerve activity with a higher sym-
athetic tone during the day than at night. However, the
ctivity in the left thoracic vagal nerve did not show a
ircadian variation. The vagal tone was not increased at
ight in these ambulatory animals. The increased vagal
ominance at night is explained by sympathetic withdrawal
ather than by an increased vagal nerve activity. This finding
as potential implications on the arrhythmogenesis in
rugada syndrome. The sympathetic nerve activity is the
rimary regulator of the L-type calcium current responsible
or phase 2 of the action potential. Because the arrhyth-
ogenic mechanism in Brugada syndrome is related in part
o the heterogeneous loss of action potential dome and
hase 2 re-entry (29), the sympathetic withdrawal at night
ould reduce the calcium entry through the L-type calcium
urrent, leading to a loss of dome of the action potential. In
ontrast, the circadian increase of the sympathetic tone
uring the day helps maintain the dome of the action
otential and prevent arrhythmia. cPD restitution and VF. Among patients with Brugada-
ype ECGs, not all are symptomatic or die suddenly. It is
nclear why some patients seem to be prone to VF but
thers are not. A report by Hayashi et al. (3), in this issue of
he Journal, provided clues to the risk of VF in patients with
rugada syndrome. The investigators performed programmed
timulation in 21 patients with type-1 ECG patterns. The
nvestigators then plotted the ARI against the preceding
iastolic interval to construct the APD restitution curve and
alculated the slope of APD restitution in all patients. Their
esults showed that the slope of APD restitution was steeper
n patients with inducible VF than in patients without
nducible VF. They concluded that the repolarization res-
itution property is a contributing factor for the propensity
f VF in patients with Brugada syndrome.
Nolasco and Dahlen (30) found that the slope of the
PD restitution is an important determinant of the stability
f the heart rhythm. Subsequent studies (31,32) have
upported the importance of APD restitution slope in
rrhythmogenesis in the animal models. Nash et al. (33)
bserved in humans a significant spatial heterogeneity of
PD restitution slope. Their computer modeling shows
hat the heterogeneity of the APD restitution slope may
rovide a substrate for arrhythmia. The work by Hayashi
t al. (3) also showed different slopes at right ventricular
pical sites and outflow tracts, suggesting the existence of
ignificant spatial heterogeneity. These findings are consis-
ent with the studies in animal models that showed the spat-
otemporal heterogeneity of cellular restitution is important
n cardiac arrhythmogenesis (34).
Recent studies have suggested that intracellular calcium
ynamics are important factors in determining the APD
estitution (35). The work by Hayashi et al. (3) suggests the
alcium dynamics might be important in determining the
nducibility of VF in Brugada syndrome patients. In addi-
ion to calcium handling and APD restitution, excitability
nd the conduction velocity restitution are also known to be
mportant factors in the development of VF (36). The
xcitability and conduction velocity are critically dependent
n the availability of the sodium current. Significantly reduced
xcitability associated with a short-coupling interval could
ead to a complete failure of conduction and the develop-
ent of wave breaks in the process. The investigators (3)
ave observed in their data longer paced QRS duration and
onduction time in patients with inducible VF than in those
ithout inducible VF, suggesting that there are differential
eduction of sodium channel activity in the 2 groups of
atients.
echanisms of arrhythmogenesis. The mechanisms of
rrhythmogenesis in Brugada syndrome can be explained by
he heterogeneous shortening of the APD on the right
entricular epicardium (Fig. 2) (18,37). Insufficient sodium
urrent and calcium current coupled with strong Ito can
esult in the loss of action potential dome and early
epolarization in some of the epicardial cells (AP1)
Fig. 2A). The same reduction of sodium current, however,
an also lead to a delayed onset of phase 2 and paradoxically
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March 25, 2008:1176–80 Editorial Commentrolongs the action potential (AP2) (Fig. 2A). The electro-
hysiological heterogeneity creates an electrical gradient
etween AP2 and AP1 (arrow, Fig. 2A), resulting in phase
re-entry. Mechanism 2 is phase 3 early afterdepolarization
38,39). Figure 2B shows a schematic of this mechanism.
cute shortening of the APD allows the intracellular calcium
o be elevated during the late phase 3 of the action potential
Fig. 2B) and activates the Na-Ca exchange current. Because
he Na-Ca exchange current exchanges 3 sodium ions
3 positive charges) with 1 calcium ion (2 positive charges),
here is a net inward (depolarizing) current that promotes
he afterdepolarization (arrow in Fig. 2B) and triggered
ctivity (40). This hypothesis is best documented in the
tria, where vagal activation strongly shortens the action
otential. Because of an association between AF and VF in
rugada syndrome patients (4), it is possible that the same
echanism is operative in both the atria and the ventricles.
The occurrence of phase 2 re-entry or triggered activity by
ate phase 3 early afterdepolarizations both predict that the
rrhythmia in Brugada syndrome should be initiated by short-
oupled premature ventricular contractions that occur during
he T wave of the preceding depolarization (Fig. 2C). How-
ver, a short-coupled premature ventricular contraction, as
hown in this case (2), was an unusual occurrence in Brugada
yndrome (41). Both reported cases have a history of elec-
rical storm (2,41), which is also unusual in patients with
rugada syndrome. The coincidental occurrence of 2 rare
henomena (the short-coupled premature ventricular contrac-
ions and electrical storms) suggests a causal link between
hem. A possible explanation is that all arrhythmias in Brugada
Figure 2 Schematics of Possible
Arrhythmogenic Mechanisms
The first beat of arrhythmia (premature ventricular contraction) might happen by
phase 2 re-entry (A) or late phase 3 early afterdepolarization (B). If the first
beat conducts to the rest of the ventricles, it results in a short-coupled prema-
ture ventricular contraction (arrow, C). The degeneration of ventricular tachy-
cardia to ventricular fibrillation occurs if the slope of the activation potential
duration restitution curve is steep (3). AP  action potential; Ca  intracellular
calcium concentration. This figure was adapted with permission from Gang et
al. (2) and Fish and Antzelevitch (23).yndrome started with phase 2 re-entry or late phase 3 early nfterdepolarization. However, in patients with only a small
mount of cells showing shortened APD, the local re-entry or
riggered activity was not able to find an immediate exit from
he right ventricle. The re-entrant wavefront propagates locally
nd finds an exit only when most of the ventricles are
epolarized, resulting in a long-coupled premature ventricular
ontraction. However, in patients with a more severe form of
he syndrome, sufficient cells had APD shortening to allow the
mmediate exit of the phase 2 re-entry or triggered activity to
oth ventricles. Therefore, only in the more severe form of the
rugada syndrome will short-coupled premature ventricular
ontractions occur. The beat-to-beat changes of T-wave mor-
hology (Fig. 1A) support the idea that the relative number of
P1 and AP2 varies from time to time. The dynamic changes
f AP1 and AP2 balance could also account for the wax and
ane of Brugada-type ECG patterns commonly observed in
any patients with Brugada syndrome (6).
anagement of patients with Brugada syndrome. The
urrent practice guidelines (42) recommend the placement of
n implantable cardioverter-defibrillator (ICD) in Brugada
yndrome patients with a previous history of cardiac arrest and
ho are receiving optimal medical therapy. This class I
ndication is supported by a prospective randomized trial
DEBUT [Defibrillator Versus beta-Blockers for Unex-
lained Death in Thailand]) that showed effective preven-
ion of sudden death by the ICD (43). The class IIA
ndications for ICD implantation include patients with a
istory of syncope and documented ventricular tachycardia
ith a history of cardiac arrest.
Drugs that inhibit the Ito (such as quinidine) and increase
he calcium current (such as isoproterenol) are recognized as
ffective treatments of the Brugada syndrome by the current
ractice guidelines (42). Belhassen et al. (44) reported that
uinidine bisulfate (1,483  240 mg/day) effectively prevents
F induction in patients with Brugada syndrome and sup-
resses spontaneous arrhythmias. A more recent study showed
hat a much lower dosage of quinidine (300 to 600 mg a day)
ay be effective in preventing VF (45). In a recent report,
soproterenol infusion (0.003  0.003 g/kg/min) completely
uppressed electrical storm of VF in all 5 patients treated (46).
ummary. The terminal T-wave inversion in Brugada
yndrome ECG is explained by the prolongation of
picardial ARI more than by the endocardial ARI when
odium current is reduced either spontaneously or by
ilsicainide infusion (5). The APD restitution character-
stics are important factors in determining the inducibil-
ty of VF. Patients with spontaneous AF have higher
ncidence of syncope and documented VF (3). However,
here are still many unanswered questions. For example,
uppression of sodium current in normal individuals failed to
roduce Brugada-type ECGs or prolong the epicardial ARI
5). The SCN5A mutation is found only in a small percentage
f the patients, and the presence of SCN5A mutation does not
redict the severity of the disease (4). The mechanism that
esulted in the association between AF and VF remains
nclear. More work is still needed to understand the mecha-
isms of arrhythmia in Brugada syndrome.
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